
Cortechs.ai provides AI-powered quantitative imaging tools that help clinicians diagnose and monitor neurological and oncological diseases. The company sells NeuroQuant® and related software as FDA 510(k)-cleared, CE-marked medical-device applications delivered via SaaS or licensing to radiologists, neurologists, oncologists, and medical institutions. Its platform uses machine learning and medical imaging algorithms for automated brain segmentation, volumetric analysis, and lesion quantification to assess atrophy, tumors, MS lesions and ARIA. The products integrate with clinical workflows and PACS, and the suite also includes NeuroAlign CT and OnQ Prostate for CT and oncology use. Cortechs.ai is deployed at over 1,400 institutions across 44 countries with more than 2,000,000 brains processed, supporting clinical care and research scale.

Cortechs.ai provides AI-powered quantitative imaging tools that help clinicians diagnose and monitor neurological and oncological diseases. The company sells NeuroQuant® and related software as FDA 510(k)-cleared, CE-marked medical-device applications delivered via SaaS or licensing to radiologists, neurologists, oncologists, and medical institutions. Its platform uses machine learning and medical imaging algorithms for automated brain segmentation, volumetric analysis, and lesion quantification to assess atrophy, tumors, MS lesions and ARIA. The products integrate with clinical workflows and PACS, and the suite also includes NeuroAlign CT and OnQ Prostate for CT and oncology use. Cortechs.ai is deployed at over 1,400 institutions across 44 countries with more than 2,000,000 brains processed, supporting clinical care and research scale.
Core product: FDA 510(k)-cleared quantitative imaging software (NeuroQuant) for neurological and oncological applications
Deployment: Deployed at 1,400+ institutions across 44 countries; 2,000,000+ brains processed
Founded: Origins 1996; incorporated / NeuroQuant released 2002
Recent funding: Series C closed Nov 20, 2024 led by Vilas Ventures (participation by Genting Berhad / Dragasac)
Clinical radiology and quantitative medical imaging for neurology and oncology
2001
Medical Equipment Manufacturing
Series C closed Nov 20, 2024; existing investor Genting Berhad (via Dragasac) participated
“Participation from strategic investor Genting Berhad and a Series C led by Vilas Ventures indicates institutional investor backing”
| Company |
|---|
The Product Manager (PM) will be responsible for setting product vision and roadmaps, establishing strategy, and managing product development execution. The PM will be responsible for our imaging and clinical decision support products. Strong candidates will have medical imaging and/or software experience. The PM must have experience creating and applying strategy and vision, the capacity to work cross-functionally, and experience leading full product management lifecycles. The PM will work externally with customers/partners and interface internally with Cortechs.ai teams to deliver high quality software and analytics solutions in a fast-paced, challenging, and creative setting. The PM will support our mission to deliver innovative products that improve patient outcomes and ensure customer satisfaction.
Key Responsibilities:
Required Experience:
Strongly Preferred: